

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Serial No. 09/163,713

Filed: September 30, 1998

For: *Nuclear Hormone Receptor Drug
Screens*

Group Art Unit: 1646

FAX RECEIVED

Examiner: Pak, M.

NOV 2 2000


Attorney Docket No. T97-012-1

GROUP 1600


CERTIFICATE OF TRANSMISSION

I hereby certify that this copy is being transmitted by facsimile to the
Comm for Patents at (703) 308-4242 on November 1, 2000.

Signature


Richard Aron OsmanTRANSMITTALThe Commissioner for Patents
Washington, DC 20231

Dear Examiner Pak:

Attached please find a copy of our response which was originally transmitted by fax (to
703-308-4242) on July 17, 2000.Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP
Richard Aron Osman, Ph.D., Reg. No. 36,627

Tel: (650) 343-4341; Fax: (650)343-4342

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Group Art Unit: 1646

Serial No. 09/163,713

Examiner: Pak, M.

Filed: September 30, 1998

Attorney Docket No. T97-012-1

For: *Nuclear Hormone Receptor Drug
Screens*

CERTIFICATE OF TRANSMISSION

I hereby certify that this copy of the application was transmitted by facsimile to the
Comm for Patents at (03) 308-4242 on July 17, 2000.

Signature

Richard Aron Osman

OFFICIAL

RESPONSEThe Assistant Commissioner for Patents
Washington, DC 20231

Dear Examiner Pak:

Thank you for the Office action mailed March 15, 2000. Please enter the following amendments:

IN THE CLAIMS

In claim 1, line 6, please change "24 or fewer" to ~~from 5 to 24~~.

Please cancel claims 12-16.

REMARKS

Amendments

Claim 1 has been amended to require at least 5 amino acids, the minimum size exemplified (see, e.g. Table 2 at p.6, line 17). This amendment introduces no new matter. A corresponding amendment was also made in copending application 09/163,713.

Restriction

The Action's argument that the recited mixtures might be used to raise antibodies is